

FDA approves Lupin's Tavaborole Topical Solution

09 February 2021 | News

Tavaborole Topical Solution, 5 per cent, is an oxaborole antifungal indicated for the topical treatment of onychomycosis of the toenails due to *Trichophyton rubrum* or *Trichophyton mentagrophytes*.



Global pharma major Lupin Limited announced that it has received approval for its Tavaborole Topical Solution, 5 per cent, from the United States Food and Drug Administration, to market a generic equivalent of Kerydin® Topical Solution, 5 per cent, of Anacor Pharmaceuticals, Inc. The product will be manufactured at Lupin's facility in Pithampur, India.

Tavaborole Topical Solution, 5 per cent, is an oxaborole antifungal indicated for the topical treatment of onychomycosis of the toenails due to *Trichophyton rubrum* or *Trichophyton mentagrophytes*. Tavaborole Topical Solution had estimated annual sales of \$76 million in the US (IQVIA MAT December 2020).